In this opening segment of this one-on-one interview series, a part of the Oncology Stakeholders Summit, Spring 2015, Michael Kolodziej, MD, and Ted Okon, MBA, discuss which stakeholders’ opinions matter most in the development of improved oncology payment models.
Mr Okon, executive director of the Community Oncology Alliance, says that the most crucial voice during the development of a payment program is the patient’s. Additionally, he discusses why insight from providers (ie, individual practitioners, group practices, and hospitals), nurses, private payers, pharmaceutical companies, and medical device manufacturers is important.
It is important to consider the opinions of payers, providers, and patients, remarks Dr Kolodziej, a national medical director of oncology strategy for Aetna. He adds that in order for a payment model to be successful, there needs to be “harmonization” among these stakeholders.
Mr Okon also discusses the progress of the State Innovation Models initiative by the Center for Medicare & Medicaid Innovation, and shares his concerns about the program’s potential in oncology. Although substantial monetary investments have been made in these programs, Mr Okon notes that not much information is available on how these programs are doing. Mr Okon explains that he feels a lot of innovation may be possible at the state level, and he would like to see more transparency and more accountability in the near future.
Watch our related Peer Exchange, Oncology Stakeholders Summit, Spring 2015
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More